<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1601256675
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOVORAPID FLEXPEN 100U\ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN ASPART
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        189.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NovoRapid<sup>&reg;</sup> is a modern insulin (insulin analogue) with a rapid-acting effect. Modern insulin products are improved versions of human insulin.</p><p>NovoRapid<sup>&reg;</sup> is used to <strong>reduce the high blood sugar level </strong>in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Treatment with NovoRapid<sup>&reg;</sup> helps to prevent complications from your diabetes.</p><p>NovoRapid<sup>&reg;</sup> will start to lower your blood sugar 10&ndash;20 minutes after you inject it, a maximum effect occurs between 1 and 3 hours after the injection and the effect lasts for 3&ndash;5 hours. Due to this short action NovoRapid<sup>&reg;</sup> should normally be taken in combination with intermediate-acting or long-acting insulin preparations.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use NovoRapid<sup>&reg;</sup></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to insulin aspart, or any of the other ingredients in this medicine (see section 6,</p><p><em>Contents of the pack and other information</em>).</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suspect hypoglycaemia (low blood sugar) is starting (see a) <em>Summary of serious and very common side effects </em>in section 4).</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If FlexPen<sup>&reg;</sup> is dropped, damaged or crushed.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it has not been stored correctly or been frozen (see section 5, <em>How to store NovoRapid<sup>&reg;</sup></em>).</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the insulin does not appear clear and colourless.</p><p>&nbsp;</p><p>If any of these applies, <strong>do not use NovoRapid<sup>&reg;</sup>. </strong>Talk with your doctor, nurse or pharmacist for advice.</p><p>&nbsp;</p><p>Before using NovoRapid<sup>&reg;</sup></p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the label to make sure it is the right type of insulin.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use a new needle for each injection to prevent contamination.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Needles and NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> must not be shared.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Some conditions and activities can affect your need for insulin. Consult your doctor:</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are ill, carry on taking your insulin and consult your doctor.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections.</p><p>&nbsp;</p><p>Skin changes at the injection site</p><p><strong>&nbsp;</strong></p><p>The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3, How to use NovoRapid). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children below 1 year of age since no clinical studies have been carried out in children below the age of 1 year.</p><p>&nbsp;</p><p>Other medicines and NovoRapid<sup>&reg;</sup></p><p><strong>Tell your doctor, nurse or pharmacist </strong>if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.</p><p>&nbsp;</p><p><strong>Your blood sugar level may fall </strong>(hypoglycaemia) if you take:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines for the treatment of diabetes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monoamine oxidase inhibitors (MAOI) (used to treat depression)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers (used to treat high blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salicylates (used to relieve pain and lower fever)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anabolic steroids (such as testosterone)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulphonamides (used to treat infections).</p><p>&nbsp;</p><p><strong>Your blood sugar level may rise </strong>(hyperglycaemia) if you take:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral contraceptives (birth control pills)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thiazides (used to treat high blood pressure or excessive fluid retention)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucocorticoids (such as &lsquo;cortisone&rsquo; used to treat inflammation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid hormones (used to treat thyroid gland disorders)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sympathomimetics (such as epinephrine [adrenaline], or salbutamol, terbutaline used to treat asthma)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body&rsquo;s metabolic processes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Danazol (medicine acting on ovulation).</p><p>&nbsp;</p><p><strong>Octreotide and lanreotide </strong>(used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.</p><p>&nbsp;</p><p><strong>Beta-blockers </strong>(used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.</p><p>&nbsp;</p><p><strong>Thiazolidinediones </strong>(class of oral antidiabetic medicines used for treatment of type 2 diabetes)</p><p>Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with thiazolidinediones and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p>&nbsp;</p><p>If you have taken any of the medicines listed here, <strong>tell your doctor, nurse or pharmacist. Drinking alcohol and taking NovoRapid<sup>&reg;</sup></strong></p><p>&nbsp;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. NovoRapid<sup>&reg;</sup> can be used during pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no restrictions on treatment with NovoRapid<sup>&reg;</sup> during breast-feeding.</p><p>&nbsp;</p><p>NovoRapid (insulin aspart) can be used in pregnancy. Data from clinical trials do not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/newborn when compared to human insulin.</p><p>&nbsp;</p><p>Administration of subcutaneous insulin aspart to pregnant rats and rabbits did not cause adverse developmental effects.</p><p>&nbsp;</p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar), preeclampsia (A complication during pregnancy characterized by sharp rise in blood pressure, leakage of large amounts of the protein albumin into the urine and swelling of the hands, feet, and face), spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Therefore, Intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimester. After delivery, insulin requirements normally return rapidly to pre-pregnancy values</p><p>&nbsp;</p><p>Ask your doctor, nurse or pharmacist for advice before taking this medicine while pregnant or breast- feeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please ask your doctor whether you can drive a car or operate a machine:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have frequent hypoglycaemia.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you find it hard to recognise hypoglycaemia.</p><p>&nbsp;</p><p>If your blood sugar is low or high, your concentration and ability to react might be affected and therefore also your ability to drive or operate a machine. Bear in mind that you could endanger yourself or others.</p><p>&nbsp;</p><p>NovoRapid<sup>&reg;</sup> has a rapid onset of effect therefore if hypoglycaemia occurs, you may experience it earlier after an injection when compared to soluble human insulin.</p><p>&nbsp;</p><p>Important information about some of the ingredients of NovoRapid<sup>&reg;</sup></p><p>NovoRapid<sup>&reg;</sup> contains less than 1 mmol sodium (23 mg) per dose, i.e. NovoRapid<sup>&reg;</sup> is essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dose and when to take your insulin</p><p>Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.</p><p>NovoRapid<sup>&reg;</sup> is generally taken immediately before a meal.</p><p>Eat a meal or snack within 10 minutes of the injection to avoid low blood sugar. When necessary, NovoRapid<sup>&reg;</sup> can be given soon after a meal. See <em>How and where to inject below for information.</em></p><p>Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor.</p><p>&nbsp;</p><p>Use in children and adolescents</p><p>NovoRapid<sup>&reg;</sup> can be used in adolescents and children aged 1 year and above instead of soluble human insulin when a rapid onset of effect is preferred. For example, when it is difficult to dose the child in relation to meals.</p><p>&nbsp;</p><p>Use in special patient groups</p><p>If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.</p><p>&nbsp;</p><p>How and where to inject</p><p>NovoRapid<sup>&reg;</sup> is for <strong>injection under the skin </strong>(subcutaneously). You must never inject yourself directly into a vein (intravenously) or muscle (intramuscularly). NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.</p><p>With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4, <em>Possible side effects</em>). The best places to give yourself an injection are: the front of your waist (abdomen), the upper arm or the front of your thighs. The insulin will work more quickly if injected into the front of your waist. You should always measure your blood sugar regularly.</p><p>&nbsp;</p><p>How to handle NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup></p><p>NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> is a pre-filled, colour-coded, disposable pen containing insulin aspart.</p><p>&nbsp;</p><p>Read carefully the instructions on how to use NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> included in this package leaflet. You must use the pen as described in the instructions on how to use NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup>.</p><p>&nbsp;</p><p>Always ensure you use the correct pen before you inject your insulin.</p><p>&nbsp;</p><p>If you take more insulin than you should</p><p>If you take too much insulin your blood sugar gets too low (hypoglycaemia). See a) <em>Summary of serious and very common side effects </em>in section 4.</p><p>&nbsp;</p><p>If you forget to take your insulin</p><p>If you forget to take your insulin, your blood sugar may get too high (hyperglycaemia). See c) <em>Effects from diabetes </em>in section 4.</p><p>&nbsp;</p><p>If you stop taking your insulin</p><p>Do not stop taking your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis. See c) <em>Effects from diabetes </em>in section 4.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of serious and very common side effects</p><p><strong>&nbsp;</strong></p><p><strong><em>Low blood sugar (hypoglycaemia) </em></strong>is a very common side effect. It may affect more than 1 in 10 people.</p><p>&nbsp;</p><p>Low blood sugar may occur if you:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject too much insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eat too little or miss a meal.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exercise more than usual.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drink alcohol (see <em>Drinking alcohol and taking NovoRapid<sup>&reg;</sup> </em>in section 2).</p><p>&nbsp;</p><p><strong>Signs of low blood sugar: </strong>Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.</p><p>&nbsp;</p><p>Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon by someone who knows how to use it. If you are given glucagon, you will need glucose or a sugar snack as soon as you are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital.</p><p>&nbsp;</p><p>What to do if you experience low blood sugar:</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets or high sugar snacks with you, just in case.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When symptoms of low blood sugar have disappeared or when blood sugar level is stabilised, continue insulin treatment as usual.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have such a low blood sugar that it makes you pass out, if you have had need for injection of glucagon, or if you have experienced many incidents of low blood sugar, talk with a doctor. The amount or timing of insulin, food or exercise may need to be adjusted.</p><p>&nbsp;</p><p>Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (become unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink due to risk of suffocation.</p><p>&nbsp;</p><p><strong><em>Serious allergic reactions </em></strong>to NovoRapid<sup>&reg;</sup> or one of its ingredients (called a systemic allergic reaction) is a very rare side effect but can potentially be life threatening. It may affect less than 1 in 10,000 people.</p><p>&nbsp;</p><p>Seek medical advice immediately:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If signs of allergy spread to other parts of your body.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice any of these signs, seek medical advice immediately.</p><p>&nbsp;</p><p><strong>Skin changes at the injection site</strong>: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect less than 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes<em>.</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of other side effects</p><p><strong>&nbsp;</strong></p><p><strong><em>Uncommon side effects</em></strong></p><p>May affect less than 1 in 100 people.</p><p>&nbsp;</p><p><strong>Signs of allergy: </strong>Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of taking your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately. See also <em>Serious allergic reactions </em>above.</p><p>&nbsp;</p><p><strong>Vision problems: </strong>When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary.</p><p>&nbsp;</p><p><strong>Swollen joints: </strong>When you start taking insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, talk to your doctor.</p><p>&nbsp;</p><p><strong>Diabetic retinopathy </strong>(an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this.</p><p>&nbsp;</p><p><strong><em>Rare side effects</em></strong></p><p>May affect less than 1 in 1,000 people.</p><p>&nbsp;</p><p><strong>Painful neuropathy </strong>(pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain. This is called acute painful neuropathy and is usually transient.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk with your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects from diabetes</p><p><strong>&nbsp;</strong></p><p><strong><em>High blood sugar (hyperglycaemia)</em></strong></p><p>&nbsp;</p><p>High blood sugar may occur if you:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have not injected enough insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Forget to inject your insulin or stop taking insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeatedly inject less insulin than you need.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Get an infection and/or a fever.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eat more than usual.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exercise less than usual.</p><p>&nbsp;</p><p>Warning signs of high blood sugar:</p><p>The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath.</p><p>&nbsp;</p><p>What to do if you experience high blood sugar:</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any of the above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately.</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These may be signs of a very serious condition called diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the FlexPen<sup>&reg;</sup> label and carton, after &lsquo;Expiry&rsquo;. The expiry date refers to the last day of that month.</p><p>Always keep the pen cap on your FlexPen<sup>&reg;</sup> when you are not using it in order to protect it from light. NovoRapid<sup>&reg;</sup> must be protected from excessive heat and light.</p><p>&nbsp;</p><p><strong>Before opening: </strong>NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> that is not being used is to be stored in the refrigerator at 2&deg;C to 8&deg;C, away from the cooling element. Do not freeze.</p><p>&nbsp;</p><p><strong>During use or when carried as a spare: </strong>You can carry your NovoRapid<sup>&reg;</sup> FlexPen<sup>&reg;</sup> with you and keep it at a temperature below 30&deg;C or in a refrigerator (2&deg;C to 8&deg;C) for up to 4 weeks. If refrigerated, keep away from the cooling element. Do not freeze.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is insulin aspart. Each ml contains 100 units of insulin aspart. Each pre-filled pen contains 300 units of insulin aspart in 3 ml solution for injection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide and water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NovoRapid® is presented as a solution for injection.
Pack sizes of 1, 5 and 10 pre-filled pens of 3 ml. Not all pack sizes may be marketed. The solution is clear and colourless.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S, Novo All&eacute;, DK-2880 Bagsv&aelig;rd, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 June 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">نوفورابِد<sup>&trade;</sup> هو إنسولين حديث (مماثل للإنسولين) له تأثير سريع المفعول. وتعرف منتجات الإنسولين الحديثة بأنها نسخ محسنة من الإنسولين البشري.</p><p dir="RTL">&nbsp;يُستخدم نوفورابِد<strong><sup>&trade;</sup> للحد من ارتفاع مستوى السكر في الدم</strong> لدى البالغين والمراهقين والأطفال الذين تتراوح أعمارهم بين سنة وما فوق المصابين بداء السكري. مرض السكري هو مرض يتسبب في عدم قدرة الجسم على إنتاج الإنسولين الكافي للتحكم في مستوى السكر بالدم. يساعد العلاج باستخدام نوفورابِد<strong><sup>&trade;</sup></strong> على تجنب المضاعفات الناتجة عن مرض السكري.</p><p dir="RTL">يبدأ نوفورابِد<sup>&trade;</sup> في خفض نسبة السكر في الدم خلال 10 إلى 20 دقيقة بعد الحقن، ويبدأ تأثيره بحد أقصى بين ساعة و3 ساعات بعد الحقن ويستمر تأثيره لمدة 3 إلى 5 ساعات. ونتيجة لهذا التأثير القصير، يجب استعمال نوفورابِد<sup>&trade;</sup> عادةً بالاقتران مع إنسولين متوسط أو طويل المفعول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحظر استعمال نوفورابِد<sup>&trade;</sup> في الحالات التالية</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية للإنسولين أسبارت أو أي مكونات أخرى تدخل في تركيب هذا الدواء (مذكورة في القسم 6<em> محتويات العبوة ومعلومات أخرى</em>).</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشك في بدء حدوث نقص نسبة السكر في الدم (انخفاض السكر في الدم) (انظر أ)<strong><em> </em></strong><em>ملخص الآثار الجانبية الخطيرة والشائعة جدا</em> في القسم 4).</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إسقاط قلم فلكس بن<sup>&trade;</sup> أو تلفه أو كسره.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يتم تخزين الدواء بشكل صحيح أو تم تجميده (انظر القسم 5،<em> كيفية تخزين نوفورابِد<sup>&trade;</sup></em>).</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يظهر شكل الإنسولين صافٍ وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت أيٌ من هذه الحالات تنطبق عليك، <strong>فلا تستخدم دواء نوفورابِد<sup>&trade;</sup>.</strong> استشر الطبيب أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل استعمال نوفورابِد<sup>&trade;</sup></strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من الملصق للتأكد من أنه النوع الصحيح من الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم دائماً إبرة جديدة لكل عملية حقن لمنع التلوث.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم مشاركة الإبر وقلم نوفورابِد<sup>&trade;</sup><sup> </sup>فلكس بن<sup>&trade;</sup>.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوفورابِد<sup>&trade;</sup> فلكس بن<sup>&trade;</sup> مناسب فقط للحقن تحت الجلد. استشر طبيبك إذا احتجت إلى حقن الإنسولين بطريقة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">قد تؤثر بعض الظروف والأنشطة في كمية الإنسولين التي تحتاجها. استشر طبيبك:</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت مشاكل بالكلى أو الكبد، أو بالغدد الكظرية، أو النخامية، أو الدرقية.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا زدت من وتيرة ممارسة التمارين أكثر من المعتاد أو تريد تغيير نظام حِميتك الغذائي المعتاد، حيث يؤثر هذا في مستوى السكر في الدم.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضاً استمر في استعمال الإنسولين واستشر طبيبك المعالج.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مسافراً خارج البلاد: قد يؤثر السفر إلى المناطق البعيدة على مقدار احتياجك من الإنسولين وتوقيت الحقن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تغيرات جلديّة في موضع الحقن</strong></p><p dir="RTL">يجب تغيير موضع الحقن للمساعدة على منع حدوث تغييرات في النسيج الدهني تحت الجلد، مثل ثخانة الجلد أو انكماشه أو ظهور تكتلات تحت الجلد. قد لا يعمل الأنسولين بفعالية كبيرة إذا حقَنتَه في منطقة متكتلة أو منكمشة أو بها ثخانة (راجع القسم 3<em>، كيفية استخدام </em><em>نوفورابِد<sup>&trade;</sup></em>). أخبر طبيبك إذا لاحظت حدوث أي تغيرات جلديّة في موضع الحقن. أخبر طبيبك إذا كنت تحقن حاليًا في هذه المناطق المصابة قبل أن تبدأ الحقن في منطقة مختلفة. قد يطلب منك طبيبك فحص مستوى السكر في الدم في أوقات أكثر تقاربًا، وأن تغيّر جرعة الأنسولين أو جرعة الأدوية الأخرى المضادة للسكري.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطي هذا الدواء للأطفال دون سن سنة واحدة، حيث لم يتم إجراء أي دراسات سريرية على الأطفال الذين تقل أعمارهم عن سنة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ونوفورابِد<sup>&trade;</sup></strong></p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة أو الصيدلي</strong> إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;تؤثر بعض الأدوية في مستوى السكر في الدم، وقد يعني هذا ضرورة تغيير جرعة الإنسولين. فيما يلي الأدوية الأكثر شيوعاً التي قد تؤثر في علاجك بالإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;قد ينخفض مستوى السكر في الدم</strong> (هبوط سكر الدم) إذا أخذت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لعلاج مرض السكري</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أوكسيديز أحادي الأمين (MAOI) (تُستخدم لعلاج الاكتئاب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا (تستخدم لعلاج ارتفاع ضغط الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات الإِنْزيم المُحَوِّل للأنجيوتنسين (ACE) - (تستخدم لعلاج بعض مشاكل القلب أو ضغط الدم المرتفع)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الساليسيلات (تُستخدم لتخفيف الألم و خفض الحمى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السترويدات الابتنائية (مثل التيستوستيرون)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجموعة السلفوناميد (تُستخدم لعلاج العدوى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يرتفع مستوى السكر في الدم</strong> (زيادة سكر الدم) إذا أخذت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل عن طريق الفم (حبوب منع الحمل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثيازيدات (يُستخدم لعلاج ارتفاع ضغط الدم أو الاحتفاظ المفرط بالسوائل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية القشرانية السكرية (مثل &quot;الكورتيزون&quot; المستخدم لعلاج الالتهابات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية (تُستخدم لعلاج اضطرابات الغدة الدرقية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحاكيات الودية (مثل الإبينيفرين [الأدرينالين]، أو السالبوتامول، أو التيربوتالين المستخدم لعلاج الربو)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون النمو (دواء لتحفيز الهيكل العظمي والنمو الجسدي وله تأثير واضح على عمليات التمثيل الغذائي في الجسم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانازول (دواء يؤثر على الإباضة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي <strong>أوكتوريوتيد ولانريوتيد</strong> (يستخدمان لعلاج ضخامة الأطراف، وهو اضطراب هرموني نادر يحدث عادة عند البالغين في منتصف العمر، وينتج عن إنتاج الغدة النخامية لهرمون النمو الزائد) إلى زيادة أو نقصان مستوى السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تضعف <strong>حاصرات بيتا</strong> (تستخدم لعلاج ارتفاع ضغط الدم) أو تكبح تماماً أعراض التحذير الأولى التي تساعدك على التعرف على نقص مستوى السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ثيازوليدينديون </strong>(فئة من الأدوية المضادة للسكري المتناولة عن طريق الفم والمستخدمة لعلاج داء السكري من النوع الثاني)</p><p dir="RTL">تعرض بعض المرضى المصابين بالنوع الثاني من الداء السكري لفترة طويلة مع أمراض القلب أو الإصابة بسكتة دماغية سابقاً وعولجوا بأدوية ثيازوليدينديون مع الإنسولين لفشل القلب. فاحرص على إبلاغ الطبيب المعالج في أقرب وقت ممكن إذا كنت تعاني من علامات فشل القلب، مثل ضيق التنفس غير العادي أو زيادة الوزن السريعة أو التورم الموضعي (وذمة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت قد تناولت أي من الأدوية المذكورة هنا، <strong>أخبر طبيبك أو الممرضة أو الصيدلي.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شرب الكحول واستعمال نوفورابِد<sup>&trade;</sup></strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الكحول، فقد تتغير حاجتك للإنسولين لأن مستوى السكر في الدم قد يرتفع أو ينخفض. ولذلك يوصى بالمراقبة الدقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً، أو تعتقدين أنكِ حامل أو تنوين الحمل، فاستشيري طبيبك قبل أخذ هذا الدواء. يمكن استخدام نوفورابِد<sup>&trade; </sup>أثناء الحمل. قد يلزم تغيير جرعة الإنسولين أثناء الحمل وبعد الولادة. ويعد التحكم الدقيق بمرض السكري، وخاصة الوقاية من هبوط سكر الدم، أمراً هاماً لصحة طفلك.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا توجد قيود على العلاج باستعمال نوفورابِد<sup>&trade;</sup> أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام نوفورابِد&trade; (إنسولين أسبارت) أثناء الحمل. لا تشير البيانات المستمدة من التجارب السريرية إلى أي أثر عكسي لإنسولين أسبارت على الحمل أو على صحة الجنين/المولود حديثًا عند مقارنته بالإنسولين البشري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتسبب إعطاء إنسولين أسبارت تحت الجلد لدى الفئران والأرانب الحوامل في آثار نمو سلبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يزيد مرض السكري المُراقَب على نحو سيء أثناء الحمل من خطر إصابة الأم بالحماض الكيتوني السكري (تراكم الحمض في الدم لأن الجسم يُحلل الدهون بدلًا من السكر)، ومقدمات الارتعاج (مضاعفة أثناء الحمل تتسم بارتفاع حاد في ضغط الدم، وتسرب كميات كبيرة من بروتين الألبومين إلى البول، وتورّم اليدين والقدمين والوجه)، وعمليات الإجهاض العفوي، والولادة المبكرة، ومضاعفات الولادة. يزيد مرض السكري المُراقَب على نحو سيء من خطر الإصابة بعيوب خلقية كبيرة، وولادة جنين ميت، واعتلال متعلق بالعملقة. ولذلك، يوصى بالتحكم في السكر في الدم ومراقبة السيدات الحوامل المريضات بالسكري على نحو مكثف أثناء فترة الحمل وعند الإقدام على الحمل. عادةً ما تنخفض الحاجة للإنسولين في الثلث الأول من فترة الحمل، وتزيد لاحقًا خلال الثلثين الثاني والثالث. وبعد الولادة، سرعان ما تعود الحاجة للإنسولين إلى قيمها التي كانت عليها قبل الحمل</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري الطبيب أو الممرضة أو الصيدلي قبل تناول هذا الدواء أثناء الحمل أو الرضاعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرجى سؤال الطبيب عما إذا كان بإمكانك قيادة سيارة أو تشغيل آلة في الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من هبوط سكر الدم بشكل متكرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجدت صعوبة في التعرف على هبوط سكر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان مستوى السكر في الدم منخفضاً أو مرتفعاً، قد يتأثر تركيزك وقدرتك على التصرف، وبالتالي قدرتك على القيادة أو تشغيل الآلات. فيرجى الانتباه إلى أنك قد تعرض نفسك أو الآخرين للخطر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتميز نوفورابِد<sup>&trade;</sup> بتأثير سريع ولذلك، إذا حدث نقص لمعدل السكر في الدم، قد تشعر بالتأثير في وقت مبكر بعد الحقن بالمقارنة مع الإنسولين البشري الذائب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة عن بعض مكونات نوفورابِد<sup>&trade;</sup></strong></p><p dir="RTL">يحتوي نوفورابِد<sup>&trade;</sup> على أقل من 1 ميليمول من الصوديوم (23 ملجم) لكل جرعة، &rlm;‫وهذا يعني أن نوفورابِد<sup>&trade;</sup> &quot;خالٍ من الصوديوم&quot; تقريباً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة وموعد جرعة الإنسولين</strong></p><p dir="RTL">استعمل دائماً الإنسولين واضبط جرعته تماماً كما نصحك طبيبك. استشر الطبيب أو الممرضة أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">يتم استعمال نوفورابِد<sup>&trade;</sup> عموماً قبل تناول الطعام مباشرةً.</p><p dir="RTL">واحرص على تناول وجبة أو وجبة خفيفة في غضون 10 دقائق من الحقن لتجنب نقص السكر بالدم. وعند الضرورة، يمكن استعمال نوفورابِد<sup>&trade;</sup> مباشرة بعد تناول الطعام. انظر <em>كيفية وموضع الحقن أدناه لمزيد من المعلومات.</em></p><p dir="RTL">ولا تغير نوع الإنسولين، إلا إذا أخبرك طبيبك بذلك. وإذا نصحك الطبیب المعالج بتغيير نوع الإنسولین إلی آخر، قد یتعین علیك ضبط الجرعة مع طبیبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استعماله للأطفال والمراهقين</strong></p><p dir="RTL">يمكن استعمال نوفورابِد<sup>&trade;</sup> مع المراهقين والأطفال الذين تبلغ أعمارهم سنة واحدة وما فوق بدلاً من الإنسولين البشري الذائب عندما يفضل الحصول على تأثير سريع. على سبيل المثال، عندما يكون من الصعب إعطاء الجرعة للطفل بسبب وجبات الطعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الدواء مع فئات خاصة من المرضى</strong></p><p dir="RTL">إذا كنت تعاني من انخفاض وظائف الكلى أو الكبد أو كان عُمرك يزيد على 65 سنة، يجب عليك التحقق من نسبة السكر في الدم بشكل أكثر انتظاماً ومناقشة تغيرات جرعة الإنسولين مع طبيبك المعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية وموضع الحقن</strong></p><p dir="RTL">نوفورابِد<sup>&trade;</sup> مخصص<strong> للحقن تحت الجلد</strong>. لا يجب مطلقاً حقن نفسك مباشرةً في الوريد أو في العضل. نوفورابِد<sup>&trade;</sup> فلكس بن<sup>&trade;</sup> مناسب فقط للحقن تحت الجلد. استشر طبيبك إذا احتجت إلى حقن الإنسولين بطريقة أخرى.</p><p dir="RTL">ومع كل حقنة يجب تغيير موضع الحقن في منطقة معينة من الجلد. فقد يقلل هذا من خطر تكون الكتل أو تورم الجلد (انظر القسم &quot;4 <em>الآثار الجانبية المحتملة</em>&quot;). وتعد أفضل الأماكن لحقن نفسك هي: الجزء الأمامي من الخصر (البطن) أو الجزء العلوي من الذراع أو الجزء الأمامي من الفخذين. سوف يعمل الإنسولين بسرعة أكبر إذا تم حقنه في الجزء الأمامي من الخصر. ولا تنسَ قياس مستوى السكر في الدم بانتظام دائماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استعمال نوفورابِد<sup>&trade;</sup> فلكس بن</strong><sup> </sup><strong><sup>&trade;</sup></strong></p><p dir="RTL">نوفورابِد<sup>&trade;</sup> فلكس بن<sup> &trade;</sup> عبارة عن قلم معبأ مسبقاً ومُرمَّز بالألوان ومخصص للاستعمال لمرة واحدة فقط يحتوي على إنسولين أسبارت</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقرأ بعناية التعليمات الخاصة بكيفية استعمال نوفورابِد<sup>&trade;</sup> فلكس بن<sup>&trade;</sup> والواردة بنشرة العبوة هذه. حيث يجب استخدام القلم كما هو موضح في التعليمات حول كيفية استعمال نوفورابِد<sup>&trade;</sup> فلكس بن<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأكد دائماً من استخدام القلم الصحيح قبل حقن الإنسولين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استعمال كمية إنسولين أكبر مما ينبغي</strong></p><p dir="RTL">في حال استعمال الكثير من الإنسولين، ستنخفض نسبة السكر في الدم جداً (هبوط سكر الدم). انظر أ) <em>ملخص الآثار الجانبية الخطيرة والشائعة جداً</em> في القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان استعمال الإنسولين</strong></p><p dir="RTL">إذا نسيت استعمال الإنسولين، فقد يرتفع مستوى السكر في الدم أكثر من اللازم (زيادة سكر الدم). انظر ج) <em>تأثيرات مرض السكري</em> في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استعمال الإنسولين</strong></p><p dir="RTL">فلا تتوقف عن استخدام الإنسولين دون التحدث إلى الطبيب الذي سيخبرك بما يجب القيام به. فهذا يمكن أن يؤدي إلى ارتفاع شديد في مستوى السكر في الدم (فرط سكر الدم الشديد) والحماض الكيتوني. انظر ج) <em>تأثيرات مرض السكري</em> في القسم 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، ينبغي استشارة طبيبك أو الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ) ملخص الآثار الجانبية الخطيرة والشائعة جداً</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يعتبر <strong><em>انخفاض السكر في الدم (هبوط سكر الدم)</em></strong> من الآثار الجانبية الشائعة جداً. قد تصيب أكثر من شخص من كل 10 أشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث انخفاض السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقنت جرعة زائدة من الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكلت كمية من الطعام أقل من اللازم أو لم تتناول إحدى الوجبات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمرنت أكثر من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تشرب الكحول (انظر <em>شرب الكحول واستعمال نوفورابِد<sup>&trade;</sup></em> في القسم 2).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات انخفاض السكر في الدم:</strong> التعرق البارد؛ شحوب الجلد وبرودته؛ صداع بالرأس؛ سرعة ضربات القلب؛ الشعور بالغثيان او القئ ؛ الشعور بالجوع المفرط؛ تغييرات مؤقتة في الرؤية؛ الشعور بالنعاس؛ الشعور بالتعب والضعف بشكل غير عادي؛ التوتر أو الرعشة؛ الشعور بالقلق؛ الشعور بالارتباك؛ صعوبة التركيز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي انخفاض سكر الدم الحاد إلى فقدان الوعي. إذا لم يتم علاج نقص مستوى السكر في الدم لفترة طويلة، قد يتسبب ذلك في تلف الدماغ (مؤقتاً أو دائماً) أو حتى الوفاة. قد تتعافى بسرعة أكبر من حالة فقدان الوعي عن طريق حقنة هرمون الجلوكاجون بواسطة شخص يعرف كيفية استخدامها. وإذا كنت تستعمل الجلوكاجون، ستحتاج إلى تناول الجلوكوز أو وجبة خفيفة سكرية بمجرد الرجوع إلى وعيك. وإذا لم تستجيب لحقن الجلوكاجون، يجب أن تذهب للمستشفى للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله إذا تعرضت لانخفاض السكر في الدم:</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت لانخفاض نسبة السكر في الدم، تناول أقراص الجلوكوز أو وجبة خفيفة أخرى عالية السكر (مثل حلوى أو بسكويت أو عصير فاكهة). ينبغي قياس مستوى السكر في الدم وأخذ قسط من الراحة. ولذلك ينبغي دائماً حمل أقراص الجلوكوز أو الوجبات الخفيفة عالية السكر معك من باب الاحتياط.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما تختفي أعراض اﻧﺨﻔﺎض ﻧﺴﺒﺔ اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم أو عند استقرار مستوى السكر في الدم، واصل العلاج المعتاد باستعمال الإنسولين.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض السكر في الدم لدرجة فقدان الوعي، أو إذا كنت بحاجة لحقن الجلوكاجون أو إذا كنت قد تعرضت للعديد من حالات انخفاض سكر الدم، عليك استشارة طبيبك. حيث قد يلزم تعديل كمية الإنسولين أو توقيت تعاطيه أو كمية الطعام المتناول أو التمارين الرياضية الممارسة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الأشخاص ذوي الصلة أنك من المصابین بمرض السكري وأطلعهم على العواقب التي قد تحدث لك، بما في ذلك خطر فقدان الوعي بسبب نقص مستوى السكر في الدم. أخبرهم أنه في حال فقدانك للوعي، يجب عليهم إسنادك إلى جانبك والحصول على المساعدة الطبية على الفور. ولا يجوز إعطاؤك أي طعام أو شراب لخطورة حدوث اختناق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>التفاعلات التحسسية الخطيرة</em></strong> لاستعمال نوفورابِد<sup>&trade;</sup> أو أحد مكوناته (يطلق عليه تفاعل الحساسية العام) هو أثر جانبي نادر للغاية ولكن يمكن أن يهدد الحياة. وقد تصيب أقل من شخص من كل 10000 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلب المشورة الطبية فوراً:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انتشرت علامات الحساسية إلى أجزاء أخرى من جسمك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت فجأة بأنك لست على ما يرام أو بدأت في التعرق أو في المرض (القيء) أو وجدت صعوبة التنفس أو شعرت بسرعة ضربات القلب أو بالدوار.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت أياً من هذه العلامات، اطلب المشورة الطبية فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تغيرات جلديّة في موقع الحقن:</em></strong> إذا حقَنتَ الأنسولين في نفس المكان، فقد ينكمش النسيج الدهني (الضمور الشحمي) أو يتضخّم (التضخّم الشحمي) (قد يصيب أقل من 1 من كل 100 شخص). قد تظهر كتل تحت الجلد أيضًا بسبب تراكم بروتين يُسمّى النشواني (الداء النشواني الجلدي؛ ولا يُعرف مدى تكرار حدوث ذلك). قد لا يعمل الأنسولين بفعالية كبيرة إذا حقَنتَه في منطقة متكتلة أو منكمشة &nbsp;أو بها ثخانة. قم بتغيير موضع الحقن عند مع حقنة للمساعدة على منع هذه التغييرات الجلدية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قائمة الآثار الجانبية الأخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية غير الشائعة</em></strong></p><p dir="RTL">قد تصيب أقل من شخص من كل 100 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علامات الحساسية:</strong> قد تحدث تفاعلات حساسية موضعية (ألم واحمرار وشرى والتهاب وقرح وتورم وحكة) في موضع الحقن. وعادةً ما تختفي هذه التفاعلات بعد بضعة أسابيع من استعمال الإنسولين. وإذا لم تختفي، أو إذا انتشرت في جميع أنحاء جسدك، استشر طبيبك على الفور. انظر أيضاً <em>ردود الفعل التحسسية الخطيرة</em> أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل الرؤية:</strong> عندما تبدأ أول جرعة علاج بالإنسولين، قد تصاب بمشاكل في الرؤية، ولكن عادة ما يكون ذلك الاضطراب مؤقتاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تورم المفاصل:</strong> عند بدء استعمال الإنسولين، قد يسبب احتباس الماء حدوث تورم حول الكاحلين والمفاصل الأخرى. وعادةً ما تختفي هذه الأعراض سريعًا. وإذا لم يكن الأمر كذلك، فيرجى التحدث مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اعتلال الشبكية السكري </strong>(مرض بالعين مرتبط بمرض السكري والذي يمكن أن يؤدي إلى فقدان الرؤية): إذا كنت تعاني من اعتلال الشبكية السكري مع تطور مستوى السكر في الدم بسرعة كبيرة، قد يزداد اعتلال الشبكية سوءاً. ولذلك يجب استشارة الطبيب المعالج في هذا الشأن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الأعراض الجانبية النادرة</em></strong></p><p dir="RTL">قد تصيب أقل من شخص من كل 1000 شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاعتلال العصبي المؤلم </strong>(ألم بسبب تلف الأعصاب): إذا كان مستوى السكر في الدم يتطور بسرعة كبيرة، قد تعاني من ألم عصبي. وهذا ما يسمى بالاعتلال العصبي المؤلم الحاد، وعادة ما يكون عابراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">في حالة إصابتك بأي آثار جانبية، استشر الطبيب أو الممرضة أو الصيدلي. يشمل هذا أية آثار جانبية محتملة غير واردة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات مرض السكري</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>&nbsp;ارتفاع السكر في الدم (فرط جلوكوز الدم)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث ارتفاع السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تحقن جرعة كافية من الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسيت حقن الإنسولين أو توقفت عن تناول الإنسولين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقنت كمية إنسولين أقل مما تحتاج إليه بشكل متكرر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بالعدوى و/أو الحمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأكل أكثر من المعتاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمرنت أقل من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات التحذيرية لارتفاع السكر في الدم:</strong></p><p dir="RTL">تظهر العلامات التحذيرية تدريجياً. وتشمل: زيادة التبول والشعور بالعطش وفقدان الشهية والشعور بالمرض (الغثيان أو القيء) والشعور بالنعاس أو التعب والشعور بالحرارة وجفاف الجلد وجفاف الفم ورائحة نفس أشبه بالفاكهة (أسيتون).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله إذا تعرضت لارتفاع مستوى السكر في الدم:</strong></p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فإذا كنت تعاني من أي من العلامات المذكورة أعلاه، اختبر مستوى السكر في الدم لديك، واختبر البول لمعرفة الكيتونات في حالة الاستطاعة، ثم اطلب المشورة الطبية على الفور.</p><p dir="RTL">►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشير هذه العلامات إلى حالة خطيرة جداً تسمى الحماض الكيتوني السكري (تراكم الحمض في الدم لأن الجسم يكسر الدهون بدلاً من السكر). وإذا لم تعالج هذه الحالة، قد تؤدي إلى الدخول في غيبوبة سكر والوفاة في أخر الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على ملصق قلم الحقن فلكس بن<sup>&trade;</sup> والعبوة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">احرص دائماً على وضع غطاء القلم على قلم فلكس بن<sup>&trade;</sup> في حال عدم استخدامه من أجل حمايته من الضوء.</p><p dir="RTL">يجب حماية نوفورابِد<sup>&trade;</sup> من الحرارة والضوء المفرط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل الفتح:</strong> يجب تخزين نوفورابِد<sup>&trade;</sup> فلكس بن<sup>&trade;</sup> غير المستعمل في الثلاجة عند درجة حرارة 2 إلى 8 درجة مئوية، بعيداً عن عنصر التبريد. يُراعى عدم التجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء الاستعمال أو عند حمله كعبوة بديلة:</strong> يمكنك حمل نوفورابِد<sup>&trade;</sup> فلكس بن<sup>&trade;</sup> معك والاحتفاظ بها في درجة حرارة تقل عن 30 درجة مئوية أو في الثلاجة (عند درجة حرارة 2 إلى 8 درجات مئوية) لمدة تصل إلى 4 أسابيع. وفي حال حفظه في الثلاجة، يراعى الاحتفاظ به بعيداً عن عنصر التبريد. يُراعى عدم التجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أية أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إنسولين أسبارت. يحتوي كل 1 مل على 100 وحدة إنسولين أسبارت. يحتوي كل قلم معبأ مسبقاً على 300 وحدة إنسولين أسبارت لكل 3 مل محلول للحقن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي جليسرول وفينول وميتاكرسول وكلوريد الزنك وثنائي هيدرات فوسفات ثنائي الصوديوم وكلوريد الصوديوم وحمض الهيدروكلوريك وهيدروكسيد الصوديوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر نوفورابِد<sup>&trade;</sup> في صورة محلول للحقن.</p><p dir="RTL">تتوفر عبوات بها قلم واحد أو 5 أقلام أو 10 أقلام للحقن معبأة مسبقاً بحجم 3 مل. لا تتوفر جميع أحجام العبوات في بعض الأسواق.</p><p dir="RTL">يتميز المحلول بأنه صافٍ وعديم اللون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المُصنعة:</strong></p><p dir="RTL">Novo Nordisk Production SAS</p><p dir="RTL">45 Avenue d&rsquo;Orl&eacute;ans</p><p dir="RTL">F-28000 Chartres</p><p dir="RTL">France</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoRapid FlexPen 100 units/ml solution for injection in pre-filled pen 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoRapid FlexPen/NovoRapid InnoLet/NovoRapid FlexTouch
1 pre-filled pen contains 3 ml equivalent to 300 units.1 ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg).
*Insulin aspart is produced in Saccharomyces cerevisiae by recombinant DNA technology. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

The solution is clear, colourless and aqueous.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Posology</p><p>The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.</p><p>&nbsp;</p><p>NovoRapid dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.</p><p>&nbsp;</p><p>Moreover NovoRapid vial and NovoRapid PumpCart can be used for continuous subcutaneous insulin infusion (CSII) in pump systems.</p><p>&nbsp;</p><p>NovoRapid vial can also be used if intravenous administration of insulin aspart, by physicians or other healthcare staff, is applicable.</p><p>&nbsp;</p><p>Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.</p><p>&nbsp;</p><p>The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50&ndash;70% of this requirement may be provided by NovoRapid and the remainder by intermediate-acting or long-acting insulin.</p><p>&nbsp;</p><p>Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.</p><p>&nbsp;</p><p>Special populations</p><p><strong>&nbsp;</strong></p><p><em>Elderly (&ge; 65 years old)</em></p><p>NovoRapid can be used in elderly patients.</p><p>In elderly patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>Renal or hepatic impairment may reduce the patient&rsquo;s insulin requirements.</p><p>In patients with renal or hepatic impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>NovoRapid can be used in children and adolescents aged 1 year and above in preference to soluble human insulin when a rapid onset of action might be beneficial, for example, in the timing of the injections in relation to meals (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p>The safety and efficacy of NovoRapid in children below 1 year of age have not been established. No data are available.</p><p>&nbsp;</p><p>Transfer from other insulin medicinal products</p><p><strong>&nbsp;</strong></p><p>When transferring from other insulin medicinal products, adjustment of the NovoRapid dose and the dose of the basal insulin may be necessary. NovoRapid has a faster onset and a shorter duration of action than soluble human insulin. When injected subcutaneously into the abdominal wall, the onset of action will occur within 10&ndash;20 minutes of injection. The maximum effect is exerted between 1 and</p><p>3 hours after the injection. The duration of action is 3 to 5 hours.</p><p>&nbsp;</p><p>Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).</p><p>&nbsp;</p><p>Method of administration</p><p><strong>&nbsp;</strong></p><p>NovoRapid is a rapid-acting insulin analogue.</p><p>NovoRapid is administered subcutaneously by injection in the abdominal wall, the thigh, the upper arm, the deltoid region or the gluteal region. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8). Subcutaneous injection in the abdominal wall ensures a faster absorption than other injection sites. Compared to soluble human insulin the faster onset of action of NovoRapid is maintained regardless of the injection site. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.</p><p>&nbsp;</p><p>Due to the faster onset of action, NovoRapid should generally be given immediately before a meal. When necessary NovoRapid can be given soon after a meal.</p><p>&nbsp;</p><p><u>NovoRapid vial/NovoRapid PumpCart</u></p><p><em>Continuous Subcutaneous Insulin Infusion (CSII)</em></p><p>NovoRapid may be used for CSII in pump systems suitable for insulin infusion. CSII should be administered in the abdominal wall. Infusion sites should be rotated.</p><p>&nbsp;</p><p>When used with an insulin infusion pump, NovoRapid should not be mixed with any other insulin medicinal products.</p><p>&nbsp;</p><p>Patients using CSII should be comprehensively instructed in the use of the pump system and use the correct reservoir and tubing for the pump (see section 6.6). The infusion set (tubing and cannula) should be changed in accordance with the instructions in the product information supplied with the infusion set.</p><p>&nbsp;</p><p>Patients administering NovoRapid by CSII must have an alternative insulin delivery method available in case of pump system failure.</p><p>&nbsp;</p><p><u>NovoRapid vial</u></p><p><em>Intravenous use</em></p><p>If necessary, NovoRapid can be administered intravenously which should be carried out by physicians or other healthcare staff.</p><p>&nbsp;</p><p>For intravenous use, infusion systems with NovoRapid 100 units/ml at concentrations from</p><p>0.05 unit/ml to 1.0 unit/ml insulin aspart in the infusion fluids 0.9% sodium chloride, 5% dextrose or 10% dextrose including 40 mmol/l potassium chloride using polypropylene infusion bags, are stable at room temperature for 24 hours.</p><p>&nbsp;</p><p>Although stable over time, a certain amount of insulin will be initially adsorbed to the material of the infusion bag. Monitoring of blood glucose is necessary during insulin infusion.</p><p>&nbsp;</p><p><em>Mixing two types of insulins</em></p><p>NovoRapid can only be mixed with NPH (Neutral Protamine Hagedorn) insulin in a syringe for subcutaneous use. When NovoRapid is mixed with NPH insulin, NovoRapid should be drawn into the syringe first, and the mixture should be injected immediately after mixing. Insulin mixtures should not be administered intravenously or used with a subcutaneous insulin infusion pump.</p><p>&nbsp;</p><p><em>Administration with a syringe</em></p><p>NovoRapid vials are for use with insulin syringes with the corresponding unit scale. See also section 6.2.</p><p>&nbsp;</p><p><u>NovoRapid Penfill</u></p><p><em>Administration with an insulin delivery system</em></p><p>NovoRapid Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. NovoRapid Penfill is only suitable for subcutaneous injections from a reusable pen. If administration by syringe or intravenous injection is necessary, a vial should be used. If administration by infusion pump is necessary, a vial or NovoRapid PumpCart should be used.</p><p>&nbsp;</p><p><u>NovoRapid FlexPen</u></p><p><em>Administration with FlexPen</em></p><p>NovoRapid FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1&ndash;60 units in increments of</p><p>1 unit. NovoRapid FlexPen is only suitable for subcutaneous injections. If administration by syringe or intravenous injection is necessary, a vial should be used. If administration by infusion pump is necessary, a vial or NovoRapid PumpCart should be used.</p><p>&nbsp;</p><p><u>NovoRapid InnoLet</u></p><p><em>Administration with InnoLet</em></p><p>NovoRapid InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. InnoLet delivers 1&ndash;50 units in increments of 1 unit. NovoRapid InnoLet is only suitable for subcutaneous injections. If administration by syringe or intravenous injection is necessary, a vial should be used. If administration by infusion pump is necessary, a vial or NovoRapid PumpCart should be used.</p><p>&nbsp;</p><p><u>NovoRapid FlexTouch</u></p><p><em>Administration with FlexTouch</em></p><p>NovoRapid FlexTouch is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexTouch delivers 1&ndash;80 units in increments of 1 unit. NovoRapid FlexTouch is only suitable for subcutaneous injections. If administration by syringe or intravenous injection is necessary, a vial should be used. If administration by infusion pump is necessary, a vial or NovoRapid PumpCart should be used.</p><p>&nbsp;</p><p><u>NovoRapid PumpCart</u></p><p><em>Administration via Continuous Subcutaneous Insulin Infusion (CSII)</em></p><p>NovoRapid PumpCart is only for use with an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps.</p><p>CSII should be administered in the abdominal wall. Infusion sites should be rotated. NovoRapid PumpCart is only suitable for CSII in pump systems suitable for insulin infusion. If administration by syringe or intravenous injection is necessary, a vial should be used.</p><p>&nbsp;</p><p>&nbsp;</p><p>For detailed user instructions, please refer to the package leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients (see section 6.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before travelling between different time zones, the patient should seek the doctor&rsquo;s advice since this may mean that the patient has to take the insulin and meals at different times.</p><p>&nbsp;</p><p><u>NovoRapid PumpCart </u></p><p><em>Misuse of NovoRapid PumpCart</em></p><p>NovoRapid PumpCart is only for use with an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps. It must not be used with other devices not designed for NovoRapid PumpCart, as this may result in incorrect insulin dosing and subsequent hyper- or hypoglycaemia.</p><p>&nbsp;</p><p>Hyperglycaemia</p><p><strong>&nbsp;</strong></p><p>Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.</p><p>&nbsp;</p><p>Hypoglycaemia</p><p><strong>&nbsp;</strong></p><p>Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.</p><p>&nbsp;</p><p>Especially in children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake, physical activities and current blood glucose level in order to minimise the risk of hypoglycaemia.</p><p>&nbsp;</p><p>Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected NovoRapid must not be injected. After stabilisation of patient&rsquo;s blood glucose adjustment of the dose should be considered (see sections 4.8 and 4.9).</p><p>&nbsp;</p><p>Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.</p><p>&nbsp;</p><p>A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.</p><p>&nbsp;</p><p>Since NovoRapid should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected.</p><p>&nbsp;</p><p>Concomitant illness, especially infections and feverish conditions, usually increases the patient&rsquo;s insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.</p><p>&nbsp;</p><p>When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.</p><p>&nbsp;</p><p>Transfer from other insulin medicinal products</p><p><strong>&nbsp;</strong></p><p>Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal, human insulin or human insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to NovoRapid from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.</p><p>&nbsp;</p><p>Injection site reactions</p><p><strong>&nbsp;</strong></p><p>As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of NovoRapid.</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p><strong>&nbsp;</strong></p><p>Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.</p><p>&nbsp;</p><p>Combination of NovoRapid with pioglitazone</p><p>&nbsp;</p><p>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and NovoRapid is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</p><p>&nbsp;</p><p>Avoidance of accidental mix-ups/medication errors</p><p><strong>&nbsp;</strong></p><p>Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between NovoRapid and other insulin products.</p><p>&nbsp;</p><p>Insulin antibodies</p><p><strong>&nbsp;</strong></p><p>Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.</p><p>&nbsp;</p><p>Traceability</p><p><strong>&nbsp;</strong></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>A number of medicinal products are known to interact with the glucose metabolism. The following substances may reduce the patient&#39;s insulin requirements:</p><p>Oral antidiabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin</p><p>converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.</p><p>&nbsp;</p><p>The following substances may increase the patient&rsquo;s insulin requirements:</p><p>Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.</p><p>&nbsp;</p><p>Beta-blockers may mask the symptoms of hypoglycaemia. Octreotide/lanreotide may either increase or decrease the insulin requirement. Alcohol may intensify or reduce the hypoglycaemic effect of insulin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>NovoRapid (insulin aspart) can be used in pregnancy. Data from two randomised controlled clinical trials (322 and 27 exposed pregnancies) do not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/newborn when compared to human insulin (see section 5.1).</p><p>&nbsp;</p><p>In animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at exposures 8-times and equal to the human subcutaneous dose of 1 unit/kg/day, respectively. Pre- and post-implantation losses and visceral/skeletal abnormalities were seen at higher exposures, which are considered secondary to maternal hypoglycemia. These effects were similar to those observed in rats administered regular human insulin</p><p>&nbsp;</p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Therefore, Intensified blood glucose control and monitoring of pregnant women with diabetes (type 1 diabetes, type 2 diabetes or gestational diabetes) are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimester. After delivery, insulin requirements normally return rapidly to pre-pregnancy values.</p><p>&nbsp;</p><p>Breast-feeding</p><p>&nbsp;</p><p>There are no restrictions on treatment with NovoRapid during breast-feeding. Insulin treatment of the nursing mother presents no risk to the baby. However, the NovoRapid dose may need to be adjusted.</p><p>&nbsp;</p><p>Fertility</p><p><strong>&nbsp;</strong></p><p>Animal reproduction studies have not revealed any differences between insulin aspart and human insu- lin regarding fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p><p>&nbsp;</p><p>Patients should be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of the safety profile</p><p>Adverse reactions observed in patients using NovoRapid are mainly due to the pharmacologic effect of insulin.</p><p>&nbsp;</p><p>The most frequently reported adverse reaction during treatment is hypoglycaemia. The frequencies of hypoglycaemia vary with patient population, dose regimens and level of glycaemic control (see section 4.8, Description of selected adverse reactions).</p><p>&nbsp;</p><p>At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur. These reactions are usually of transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p><strong>&nbsp;</strong></p><p>Adverse reactions listed below are based on clinical trial data and classified according to MedDRA frequency and System Organ Class. Frequency categories are defined according to the following convention: Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top; width:317px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:196px"><p>Uncommon &ndash; Urticaria, rash, eruptions</p></td></tr><tr><td style="vertical-align:top; width:196px"><p>Very rare &ndash; Anaphylactic reactions*</p></td></tr><tr><td style="vertical-align:top; width:317px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:196px"><p>Very common &ndash; Hypoglycaemia*</p></td></tr><tr><td style="vertical-align:top; width:317px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:196px"><p>Rare &ndash; Peripheral neuropathy (painful neuropathy)</p></td></tr><tr><td style="vertical-align:top; width:317px"><p>Eye disorders</p></td><td style="vertical-align:top; width:196px"><p>Uncommon &ndash; Refraction disorders</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:518px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:200px"><p>Uncommon &ndash; Diabetic retinopathy</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:200px"><p>Uncommon &ndash; Lipodystrophy*</p></td></tr><tr><td style="vertical-align:top; width:200px"><p>Not known &ndash; Cutaneous amyloidosis*&dagger;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:200px"><p>Uncommon &ndash; Injection site reactions</p></td></tr><tr><td style="vertical-align:top; width:200px"><p>Uncommon &ndash; Oedema</p></td></tr></tbody></table><p>* see section 4.8, Description of selected adverse reactions.</p><p>&dagger; ADR from postmarketing sources.</p><p>&nbsp;</p><p>Description of selected adverse reactions</p><p><strong>&nbsp;</strong></p><p><em>Anaphylactic reactions:</em></p><p>The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life threatening.</p><p>&nbsp;</p><p><em>Hypoglycaemia:</em></p><p>The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death.</p><p>The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.</p><p>&nbsp;</p><p>In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control. During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders:</em></p><p>Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</p><p>&nbsp;</p><p>Paediatric population</p><p><strong>&nbsp;</strong></p><p>Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general population.</p><p>&nbsp;</p><p>Other special populations</p><p><strong>&nbsp;</strong></p><p>Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in the elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p><strong>&nbsp;</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>Please report adverse drug events to:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient&rsquo;s requirement are administered:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar-containing products.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by physicians or other healthcare staff. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, fast-acting. ATC code: A10AB05.</p><p>&nbsp;</p><p>Mechanism of action and pharmacodynamic effects</p><p><strong>&nbsp;</strong></p><p>The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.</p><p>&nbsp;</p><p>NovoRapid produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. NovoRapid has a shorter duration of action compared to soluble human insulin after subcutaneous injection.</p><p>&nbsp;</p><p><img alt="" width="740" height="532" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>Fig. I. Blood glucose concentrations following a single pre-meal dose of NovoRapid injected immediately before a meal (solid curve) or soluble human insulin administered 30 minutes before a meal (hatched curve) in patients with type 1 diabetes mellitus.</p><p>&nbsp;</p><p>When NovoRapid is injected subcutaneously, the onset of action will occur within 10 to 20 minutes of injection. The maximum effect is exerted between 1 and 3 hours after injection. The duration of action is 3 to 5 hours.</p><p>&nbsp;</p><p>Clinical efficacy</p><p><strong>&nbsp;</strong></p><p>Clinical trials in patients with type 1 diabetes have demonstrated a lower postprandial blood glucose with NovoRapid compared to soluble human insulin (Fig. I). In two long-term open label trials in patients with type 1 diabetes comprising 1070 and 884 patients, respectively, NovoRapid reduced glycated haemoglobin by 0.12 [95% C.I. 0.03; 0.22] percentage points and by 0.15 [95% C.I. 0.05; 0.26] percentage points compared to human insulin; a difference of limited clinical significance.</p><p>&nbsp;</p><p>Clinical trials in patients with type 1 diabetes have demonstrated a reduced risk of nocturnal hypoglycaemia with insulin aspart compared with soluble human insulin. The risk of daytime hypoglycaemia was not significantly increased.</p><p>&nbsp;</p><p>Insulin aspart is equipotent to soluble human insulin on a molar basis.</p><p>&nbsp;</p><p>Special populations</p><p><strong>&nbsp;</strong></p><p><em>Elderly (&ge; 65 years old)</em></p><p>A randomised, double-blind cross-over PK/PD trial comparing insulin aspart with soluble human insulin was performed in elderly patients with type 2 diabetes (19 patients aged 65&ndash;83 years, mean age 70 years). The relative differences in the pharmacodynamic properties (GIR<sub>max</sub>,AUC<sub>GIR,</sub> <sub>0&ndash;120</sub> <sub>min</sub>) between insulin aspart and soluble human insulin in the elderly were similar to those seen in healthy subjects and in younger patients with diabetes.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>A clinical trial comparing preprandial soluble human insulin with postprandial insulin aspart was performed in small children (20 patients aged 2 to less than 6 years, studied for 12 weeks, among those four were younger than 4 years old) and a single dose PK/PD trial was performed in children (6&ndash;</p><p>12 years) and adolescents (13&ndash;17 years). The pharmacodynamic profile of insulin aspart in children was similar to that seen in adults.</p><p>&nbsp;</p><p>The efficacy and safety of NovoRapid given as bolus insulin in combination with either insulin detemir or insulin degludec as basal insulin has been studied for up to 12 months, in two randomised controlled clinical trials in adolescents and children aged 1 to less than 18 years (n=712). The trials included 167 children aged 1&ndash;5 years, 260 aged 6&ndash;11 and 285 aged 12&ndash;17. The observed improvements in HbA1c and the safety profiles were comparable between all age groups.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>A clinical trial comparing safety and efficacy of insulin aspart vs. human insulin in the treatment of pregnant women with type 1 diabetes (322 exposed pregnancies (insulin aspart: 157; human insulin: 165)) did not indicate any adverse effect of insulin aspart on pregnancy or on the health of the foetus/newborn.</p><p>In addition the data from a clinical trial including 27 women with gestational diabetes randomised to treatment with insulin aspart vs. human insulin (insulin aspart: 14; human insulin: 13) showed similar safety profiles between treatments.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption, distribution and elimination</p><p>In NovoRapid substitution of amino acid proline with aspartic acid at position B28 reduces the tendency to form hexamers as observed with soluble human insulin. NovoRapid is therefore more rapidly absorbed from the subcutaneous layer compared to soluble human insulin.</p><p>&nbsp;</p><p>The time to maximum concentration is, on average, half of that for soluble human insulin. A mean maximum plasma concentration of 492&plusmn;256 pmol/l was reached 40 (interquartile range: 30&ndash;40) minutes after a subcutaneous dose of 0.15 unit/kg bodyweight in type 1 diabetic patients. The insulin concentrations returned to baseline about 4 to 6 hours after dose. The absorption rate was somewhat slower in type 2 diabetic patients, resulting in a lower C<sub>max</sub> (352&plusmn;240 pmol/l) and later t<sub>max</sub> (60 (interquartile range: 50&ndash;90) minutes). The intra-individual variability in time to maximum concentration is significantly less for NovoRapid than for soluble human insulin, whereas the intra- individual variability in Cmax for NovoRapid is larger.</p><p>&nbsp;</p><p>Special populations</p><p><strong>&nbsp;</strong></p><p><em>Elderly (&ge; 65 years old)</em></p><p>The relative differences in pharmacokinetic properties between insulin aspart and soluble human insulin in elderly patients (65&ndash;83 years, mean age 70 years) with type 2 diabetes were similar to those observed in healthy subjects and in younger patients with diabetes. A decreased absorption rate was observed in elderly patients, resulting in a later tmax (82 (interquartile range: 60&ndash;120) minutes), whereas Cmax was similar to that observed in younger patients with type 2 diabetes and slightly lower than in patients with type 1 diabetes.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>A single dose pharmacokinetic study of insulin aspart was performed in 24 subjects with hepatic function ranging from normal to severely impaired. In patients with hepatic impairment, absorption rate was decreased and more variable, resulting in delayed tmax from about 50 min in subjects with normal hepatic function to about 85 min in patients with moderate and severe hepatic impairment. AUC, Cmax and CL/F were similar in patients with reduced hepatic function compared with subjects with normal hepatic function.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>A single dose pharmacokinetic study of insulin aspart in 18 subjects with renal function ranging from normal to severely impaired was performed. No apparent effect of creatinine clearance values on AUC, Cmax, CL/F and tmax of insulin aspart was found. Data were limited in patients with moderate and severe renal impairment. Patients with renal failure necessitating dialysis treatment were not investigated.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetic and pharmacodynamic properties of NovoRapid were investigated in children (6&ndash;12 years) and adolescents (13&ndash;17 years) with type 1 diabetes. Insulin aspart was rapidly absorbed in both age groups, with similar tmax as in adults. However, Cmax differed between the age groups, stressing the importance of the individual titration of NovoRapid.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development.</p><p>&nbsp;</p><p>In <em>in vitro </em>tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin. Studies also demonstrate that the dissociation of binding to the insulin receptor of insulin aspart is equivalent to human insulin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycerol</p><p>Phenol</p><p>Metacresol</p><p>Zinc chloride</p><p>Disodium phosphate dihydrate</p><p>Sodium chloride</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Substances added to NovoRapid may cause degradation of insulin aspart.</p><p>This medicinal product must not be diluted or mixed with other medicinal products except for mixing with NPH (Neutral Protamine Hagedorn) insulin in a syringe for subcutaneous use, or with infusion fluids as described in section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before opening: 30 months.

NovoRapid vial/NovoRapid Penfill/NovoRapid FlexPen/NovoRapid InnoLet/NovoRapid FlexTouch During use or when carried as a spare: The product must be stored for a maximum of 4 weeks. Store below 30°C.

NovoRapid PumpCart
During use or when carried as a spare: NovoRapid PumpCart carried as a spare can be kept for up to 2 weeks below 30°C. Thereafter it can be used for up to 7 days below 37°C in an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For storage conditions of the medicinal product, see section 6.3. <u>Before opening:</u> Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p><u>NovoRapid vial/NovoRapid Penfill</u></p><p><u>During use or when carried as a spare:</u> Store below 30&deg;C. Do not refrigerate. Do not freeze. Keep the vial/cartridge in the outer carton in order to protect from light.</p><p>&nbsp;</p><p><u>NovoRapid FlexPen/NovoRapid FlexTouch</u></p><p><u>During use or when carried as a spare:</u> Store below 30˚C. Can be stored in a refrigerator (2˚C &ndash; 8˚C). Do not freeze.</p><p>Keep the pen cap on the pen in order to protect from light.</p><p>&nbsp;</p><p><u>NovoRapid InnoLet</u></p><p><u>During use or when carried as a spare:</u> Store below 30&deg;C. Do not refrigerate. Do not freeze. Keep the pen cap on the pen in order to protect from light.</p><p>&nbsp;</p><p><u>NovoRapid PumpCart</u></p><p><u>During use or when carried as a spare:</u> Store below 37&deg;C (in use) or store below 30&deg;C (carried as a spare). Do not refrigerate. Do not freeze.</p><p>Keep the cartridge in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>NovoRapid vial</u></p><p>10 ml solution in vial (type 1 glass) closed with a disc (bromobutyl/polyisoprene rubber) and a protective tamper-proof plastic cap.</p><p>&nbsp;</p><p>Pack sizes of 1 or 5 vials of 10 ml or a multipack containing 5 packs of 1 x 10 ml vial. Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>NovoRapid Penfill</u></p><p>3 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene).</p><p>Pack sizes of 5 and 10 cartridges. Not all pack sizes may be marketed. <u>NovoRapid FlexPen</u></p><p>3 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene.</p><p>&nbsp;</p><p>Pack sizes of 1 (with or without needles), 5 (without needles) and 10 (without needles) pre-filled pens. Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>NovoRapid InnoLet</u></p><p>3 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene.</p><p>Pack sizes of 1, 5 and 10 pre-filled pens. Not all pack sizes may be marketed. <u>NovoRapid FlexTouch</u></p><p>3 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure</p><p>(bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene.</p><p>&nbsp;</p><p>Pack sizes of 1 (with or without needles), 5 (without needles) or a multipack with 2 x 5 (without needles) pre-filled pens of 3 ml. Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>NovoRapid PumpCart</u></p><p>1.6 ml solution in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene).</p><p>&nbsp;</p><p>Pack size of 5 cartridges and a multipack containing 25 (5 packs of 5) cartridges. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use this medicinal product if you notice that the solution is not clear, colourless and aqueous. NovoRapid which has been frozen must not be used.</p><p>The patient should be advised to discard the needle after each injection.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Needles, syringes, cartridges, pre-filled pens and infusion sets must not be shared. The cartridge must not be refilled.</p><p><u>NovoRapid vial</u></p><p>NovoRapid may be used in an infusion pump system (CSII) as described in section 4.2. Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.</p><p>&nbsp;</p><p><u>NovoRapid PumpCart</u></p><p>NovoRapid PumpCart is a pre-filled cartridge ready for use directly in the pump. Please refer to the package leaflet where detailed instructions for use are provided.</p><p>&nbsp;</p><p>To ensure correct dosing, NovoRapid PumpCart must not be used in an insulin pen.</p><p>&nbsp;</p><p>NovoRapid PumpCart is only for use with an insulin infusion pump system designed to be used with this cartridge, such as the Accu-Chek Insight and YpsoPump insulin pumps, as described in section</p><p>4.2. Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>